Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Primary Hyperparathyroidism: Non-classical Manifestations

The recruitment status of this study is unknown because the information has not been verified recently.
Verified August 2012 by Columbia University.
Recruitment status was  Active, not recruiting
Information provided by (Responsible Party):
Shonni J. Silverberg, Columbia University Identifier:
First received: February 6, 2007
Last updated: August 7, 2012
Last verified: August 2012

This is a research study to investigate cardiovascular health in people with mild hyperparathyroidism. Previous research has suggested that severe hyperparathyroidism may be associated with abnormalities in the heart and blood vessels. It is unclear whether mild hyperparathyroidism affects cardiovascular health. This study involves the investigation of the heart and blood vessels of people with mild hyperparathyroidism. Various non-invasive laboratory and radiological test to assess cardiovascular and bone health will be done at set intervals over the course of 2 years. It is our hypothesis that patients with primary hyperparathyroidism will have subtle abnormalities in their cardiovascular system. Using state-of-the art techniques that are sufficiently sensitive to detect these subtle abnormalities, we will define cardiovascular features of this disease that have, up to now, eluded clear definition. We expect taht the extent of these findings will be related to the severity of the underlying primary hyperparathyroidism. We further hypothesize that cardiovascular manifestations may regress with successful cure of the hyperparathyroid state.

Primary Hyperparathyroidism

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Primary Hyperparathyroidism: Non-classical Manifestations

Resource links provided by NLM:

Further study details as provided by Columbia University:

Biospecimen Retention:   Samples Without DNA

Specimens of frozen serum will be retained for possible future analyses.

Enrollment: 58
Study Start Date: October 2005
Estimated Study Completion Date: December 2012
Primary Completion Date: November 2009 (Final data collection date for primary outcome measure)
Detailed Description:

This study involves a total of 4 visits over a 2-year period. A variety of tests to evaluate your cardiovascular and bone health are performed. The details and timing of the tests are explained below.

VISIT #1 During the first visit, a research doctor or assistant explains the procedures in detail and answers questions. Blood is drawn (about 1-2 tablespoons) to confirm the diagnosis of hyperparathyroidism and get baseline blood values.

VISIT #2-4 During the following visits, a variety of procedures are performed to evaluate cardiovascular and bone health. The details of the procedures and when they will be performed are outlined below.

  1. Blood tests are performed at each visit. Approximately 1-2 tablespoons of blood will be drawn at each visit.
  2. A 24-hour urine collection is done 3 times during the 2 year study.
  3. Bone mineral density testing (known as DXA) is performed at baseline, 12 and 24 months after enrollment.
  4. Carotid Ultrasound: At the baseline visit, 12 and 24 months after enrollment, carotid ultrasound is performed.
  5. Echocardiogram: At the baseline visit, 12 and 24 months after enrollment, an echocardiogram is performed.
  6. Endothelial Function: At baseline, 6 and 12 months after enrollment, flow mediated dilation of the brachial artery is performed.

Ages Eligible for Study:   50 Years to 75 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

Adults age 50 to 75 with Primary Hyperparathyroidism


Inclusion Criteria:

-Primary Hyperparathyroidism

Exclusion Criteria:

  • Current use of oral bisphosphonates
  • Addition or change in cholesterol lowering medication
  • impaired renal function (creatinine >2.0 mg/dl)
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00432939

United States, New York
Metabolic Bone Diseases Unit
New York, New York, United States, 10032
Sponsors and Collaborators
Columbia University
Principal Investigator: Shonni J Silverberg, MD Columbia University
  More Information

No publications provided

Responsible Party: Shonni J. Silverberg, Professor of Medicine, Endocrinology, Columbia University Identifier: NCT00432939     History of Changes
Other Study ID Numbers: AAAB1955, R01DK066329
Study First Received: February 6, 2007
Last Updated: August 7, 2012
Health Authority: United States: Federal Government

Keywords provided by Columbia University:
Primary Hyperparathyroidism

Additional relevant MeSH terms:
Hyperparathyroidism, Primary
Endocrine System Diseases
Parathyroid Diseases processed this record on March 01, 2015